# Reference Capital SA

> Reference Capital SA is a VC fund in Geneva backing Software and Health Care. See 54 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Geneva, Switzerland
- Total investments: 54
- Last investment: Jan 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/referencecap
- Website: https://www.referencecap.com/

Reference Capital SA is a VC fund in Geneva focused on Software and Health Care. Since our inception in 2019, we have been dedicated to building and advising private investment portfolios for institutional and private clients. Through our funds of funds, direct investments, and tailored advisory services, we provide exclusive access to disruptive technology opportunities, empowering our clients to invest at the forefront ofinnovation.

## Contacts

5 contacts available for Reference Capital SA. Shizune tracks 7 team members at Reference Capital SA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/Reference-Capital-SA?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 9 | 17% |
| Health Care | 9 | 17% |
| Biotechnology | 9 | 17% |
| Medical | 8 | 15% |
| Manufacturing | 7 | 13% |

63 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 20% |
| Series C | 9 | 17% |
| Series B | 6 | 11% |
| Series D | 6 | 11% |
| Funding Round | 6 | 11% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 18 | 33% |
| Switzerland | 7 | 13% |
| United Kingdom | 3 | 6% |
| Germany | 2 | 4% |
| Canada | 1 | 2% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edouard Lingjaerde | Associate | 0 | https://shizune.co/investors/profile/edouard-lingjaerde |
| Ellina Knudsen | Strategic Research Lead | 0 | https://shizune.co/investors/profile/ellina-knudsen |
| Hélène van Berchem | Manager; Head of Sustainability | 0 | https://shizune.co/investors/profile/h%C3%A9l%C3%A8ne-van-berchem |
| José Galeano | Managing Partner | 0 | https://shizune.co/investors/profile/jos%C3%A9-galeano |
| Julien Erdmann | Finance Manager | 0 | https://shizune.co/investors/profile/julien-erdmann |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Wayve | Wayve develops autonomous driving technology using end-to-end deep learning models that enable vehicles to navigate complex urban environments. The company builds AI software that learns directly from data collected through cameras and sensors, reducing reliance on high-definition maps and rule-based systems. Its approach focuses on embodiedintelligence, where the system improves driving performance through large-scale real-world training and simulation. Wayve partners with automotive manufacturers and fleet operators to integrate its driving software into production vehicles. The platform is designed to adapt to different geographies and driving conditions through continuous learning and model refinement. | $200M | Series B | Jan 17, 2022 |  |
| Kingdom | Kingdom Supercultures create microbial cultures that help food manufacturers to create new foods with boosted benefits. It re-assembles nature's microbes into new combinations, creating plant-based foods that taste like dairy, low-alcohol beverages with full flavor, and natural preservatives that work as well as artificial ones.They workwith clients across diverse industries including food, beverage, personal care, beauty, and more. Their technology comprises an expansive biobank of GRAS microbial strains, high-resolution strain characterization, and new algorithms for predicting and assembling microbial communities. | $25M | Series A | Oct 05, 2021 |  |
| All Day Kitchens | Virtual Kitchen operates as a platform that empowers restaurants to take full advantage of the delivery opportunity. Its delivery-optimized kitchens and technology unlock delivery coverage with minimal upfront investment. The company was founded in 2018 and is headquartered in San Francisco, California. | $65M | Series C | Oct 01, 2021 |  |
| T3 Pharmaceuticals | The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatmentsusing live bacteria. | $26.9M | Series C | Jul 22, 2020 |  |
| Monzo | Monzo (previously Mondo) is a bank for people who live their lives on their smartphones and is targeted at people who want to get things done in a click and who don’t see the need for branches and cheque books. The platform is focussed on building the best current account in the world and ultimately working with a range of other providers so thatMonzo can be an intelligent hub for your entire financial life. | $81.8M | Series G | Jun 16, 2020 |  |
| T3 Pharmaceuticals | The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatmentsusing live bacteria. | $14M | Series B | Sep 26, 2019 |  |
| SOPHiA GENETICS | SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and differentdiagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory and biopharma institutions globally. | $15M | Series C | Dec 16, 2015 |  |
| NovImmune | NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. |  |  | Jun 01, 2012 |  |
| Neocutis | NEOCUTIS is dedicated to being the most admired, trusted and innovative physician-dispensed skincare brand. NEOCUTIS strives to fulfill this mission by developing exclusive technology platforms based on cutting-edge scientific research. Incorporating targeted technologies into luxurious product formulas enables NEOCUTIS to deliver innovativeskincare solutions that address key skincare concerns, including the signs of aging, discoloration, oxidative stress, skin redness and dryness. |  | Secondary Market | Sep 15, 2011 |  |
| Nexx Systems | NEXX Systems, Inc. provides processing equipment for wafer-level packaging applications. It offers sputter deposition, electro-deposition plating, and plasma cleaning systems. The company’s systems and technologies focus on flip chip advanced packaging, including wafer bumping, wafer cleaning, photoresist strip, and related technologies. Itselectro-deposition systems are designed for long deposition time processes required in applications, such as gold and solder wafer bumping, redistribution layers, and various MEMS layers. The company’s systems offer processing technology to the areas of compound semiconductors, hard disk drive head manufacturing, and ink jet printing. NEXX Systems has representatives and distributors in the United States, Germany, Italy, France, Switzerland, China, Israel, Korea, Japan, Singapore, and Taiwan. NEXX Systems, Inc. was formerly known as Plasmaquest Astex. NEXX Systems, Inc. was founded in 2001 and is headquartered in Billerica, Massachusetts. | $4M | Series D | Oct 27, 2009 |  |

10 of 54 investments shown.

## Co-investors
- [VI Partners](https://shizune.co/investors/profile/vi-partners) — VC Fund, 4 deals together
- [Neomed Management](https://shizune.co/investors/profile/neomed-management) — VC Fund, 3 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Enterprise Partners](https://shizune.co/investors/profile/enterprise-partners) — VC Fund, 2 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Reference Capital SA invest in?

Reference Capital SA invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series C stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Reference Capital SA?

Public channels for Reference Capital SA include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Reference Capital SA?

The team at Reference Capital SA includes Edouard Lingjaerde (Associate), Ellina Knudsen (Strategic Research Lead) and Hélène van Berchem (Manager; Head of Sustainability), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co